Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Neurobiol Aging ; 105: 1-15, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34004491

RESUMEN

The age-related loss of GABA in the inferior colliculus (IC) likely plays a role in the development of age-related hearing loss. Perineuronal nets (PNs), specialized aggregates of extracellular matrix, increase with age in the IC. PNs, associated with GABAergic neurotransmission, can stabilize synapses and inhibit structural plasticity. We sought to determine whether PN expression increased on GABAergic and non-GABAergic IC cells that project to the medial geniculate body (MG). We used retrograde tract-tracing in combination with immunohistochemistry for glutamic acid decarboxylase and Wisteria floribunda agglutinin across three age groups of Fischer Brown Norway rats. Results demonstrate that PNs increase with age on lemniscal and non-lemniscal IC-MG cells, however two key differences exist. First, PNs increased on non-lemniscal IC-MG cells during middle-age, but not until old age on lemniscal IC-MG cells. Second, increases of PNs on lemniscal IC-MG cells occurred on non-GABAergic cells rather than on GABAergic cells. These results suggest that synaptic stabilization and reduced plasticity likely occur at different ages on a subset of the IC-MG pathway.


Asunto(s)
Envejecimiento/patología , Neuronas GABAérgicas/patología , Neuronas GABAérgicas/fisiología , Colículos Inferiores/citología , Colículos Inferiores/patología , Red Nerviosa/patología , Red Nerviosa/fisiopatología , Tálamo/citología , Tálamo/patología , Animales , Vías Auditivas/fisiología , Cuerpos Geniculados/citología , Cuerpos Geniculados/patología , Glutamato Descarboxilasa/metabolismo , Pérdida Auditiva/etiología , Pérdida Auditiva/patología , Masculino , Lectinas de Plantas , Ratas , Receptores N-Acetilglucosamina
2.
Acta Neuropathol Commun ; 8(1): 208, 2020 11 30.
Artículo en Inglés | MEDLINE | ID: mdl-33256853

RESUMEN

Alcohol affects multiple neurotransmitter systems, notably the GABAergic system and has been recognised for a long time as particularly damaging during critical stages of brain development. Nevertheless, data from the literature are most often derived from animal or in vitro models. In order to study the production, migration and cortical density disturbances of GABAergic interneurons upon prenatal alcohol exposure, we performed immunohistochemical studies by means of the proliferation marker Ki67, GABA and calretinin antibodies in the frontal cortical plate of 17 foetal and infant brains antenatally exposed to alcohol, aged 15 weeks' gestation to 22 postnatal months and in the ganglionic eminences and the subventricular zone of the dorsal telencephalon until their regression, i.e., 34 weeks' gestation. Results were compared with those obtained in 17 control brains aged 14 weeks of gestation to 35 postnatal months. We also focused on interneuron vascular migration along the cortical microvessels by confocal microscopy with double immunolabellings using Glut1, GABA and calretinin. Semi-quantitative and quantitative analyses of GABAergic and calretininergic interneuron density allowed us to identify an insufficient and delayed production of GABAergic interneurons in the ganglionic eminences during the two first trimesters of the pregnancy and a delayed incorporation into the laminar structures of the frontal cortex. Moreover, a mispositioning of GABAergic and calretininergic interneurons persisted throughout the foetal life, these cells being located in the deep layers instead of the superficial layers II and III. Moreover, vascular migration of calretininergic interneurons within the cortical plate was impaired, as reflected by low numbers of interneurons observed close to the cortical perforating vessel walls that may in part explain their abnormal intracortical distribution. Our results are globally concordant with those previously obtained in mouse models, in which alcohol has been shown to induce an interneuronopathy by affecting interneuron density and positioning within the cortical plate, and which could account for the neurological disabilities observed in children with foetal alcohol disorder spectrum.


Asunto(s)
Consumo de Bebidas Alcohólicas , Encéfalo/embriología , Calbindina 2/metabolismo , Trastornos del Espectro Alcohólico Fetal/metabolismo , Feto/embriología , Interneuronas/metabolismo , Antígeno Ki-67/metabolismo , Efectos Tardíos de la Exposición Prenatal/metabolismo , Ácido gamma-Aminobutírico/metabolismo , Alcoholismo , Consumo Excesivo de Bebidas Alcohólicas , Encéfalo/metabolismo , Encéfalo/patología , Estudios de Casos y Controles , Movimiento Celular , Femenino , Trastornos del Espectro Alcohólico Fetal/patología , Feto/metabolismo , Feto/patología , Lóbulo Frontal/embriología , Lóbulo Frontal/metabolismo , Lóbulo Frontal/patología , Neuronas GABAérgicas/metabolismo , Neuronas GABAérgicas/patología , Humanos , Lactante , Recién Nacido , Interneuronas/patología , Masculino , Embarazo , Complicaciones del Embarazo , Segundo Trimestre del Embarazo , Efectos Tardíos de la Exposición Prenatal/patología , Telencéfalo/embriología , Telencéfalo/metabolismo , Telencéfalo/patología
3.
Neuropharmacology ; 136(Pt A): 56-67, 2018 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-29471054

RESUMEN

Absence seizures (ASs) are associated with abnormalities in gamma-aminobutyric acid (GABA) neurotransmission in the thalamus and the cortex. In the present study, we used light microscopy GABA immunocytochemistry to quantify the GABA-immunoreactive (GABA-IR) neurons and neuropil in the thalamic ventral basal (VB) nucleus, the nucleus reticularis thalami (NRT), the dorsal lateral geniculate (dLGN), the primary motor cortex (M1) and perioral region of the somatosensory cortex (S1po) of genetic absence epilepsy rats from Strasbourg (GAERS). We used both the relative non-epileptic control (NEC) and normal Wistar rats as control strains, and investigated GABA immunostaining at postnatal day 15 (P15), P25, and P90. The main findings were i) an increase in GABA-IR neuropil in the VB at P25 and P90 in GAERS but not in NEC and Wistar rats; ii) an increase in NRT GABA-IR neurons in GAERS and NEC, but not Wistar, rats at both P25 and P90; and iii) an increase in GABA-IR neuron density in S1po of GAERS at P25 and P90 and in Wistar at P90. These results indicate that the increased GABAergic innervation in the VB at P25 most likely contributes to the enhanced tonic inhibition observed in GAERS prior to AS onset, whereas the lack of any anatomo-morphological GABAergic differences in GAERS S1po suggests that functional more than structural abnormalities underlie the origin of cortical paroxysms in S1po of this AS model. This article is part of the "Special Issue Dedicated to Norman G. Bowery".


Asunto(s)
Corteza Cerebral/crecimiento & desarrollo , Corteza Cerebral/metabolismo , Epilepsia Tipo Ausencia/metabolismo , Tálamo/crecimiento & desarrollo , Tálamo/metabolismo , Ácido gamma-Aminobutírico/metabolismo , Animales , Corteza Cerebral/patología , Modelos Animales de Enfermedad , Epilepsia Tipo Ausencia/patología , Neuronas GABAérgicas/metabolismo , Neuronas GABAérgicas/patología , Vías Nerviosas/crecimiento & desarrollo , Vías Nerviosas/metabolismo , Vías Nerviosas/patología , Ratas Wistar , Convulsiones/metabolismo , Convulsiones/patología , Especificidad de la Especie , Tálamo/patología
4.
Diabetes ; 67(3): 486-495, 2018 03.
Artículo en Inglés | MEDLINE | ID: mdl-29212780

RESUMEN

Diabetes mellitus (DM) is associated with increased plasma levels of arginine-vasopressin (AVP), which may aggravate hyperglycemia and nephropathy. However, the mechanisms by which DM may cause the increased AVP levels are not known. Electrophysiological recordings in supraoptic nucleus (SON) slices from streptozotocin (STZ)-induced DM rats and vehicle-treated control rats revealed that γ-aminobutyric acid (GABA) functions generally as an excitatory neurotransmitter in the AVP neurons of STZ rats, whereas it usually evokes inhibitory responses in the cells of control animals. Furthermore, Western blotting analyses of Cl- transporters in the SON tissues indicated that Na+-K+-2Cl- cotransporter isotype 1 (a Cl- importer) was upregulated and K+-Cl- cotransporter isotype 2 (KCC2; a Cl- extruder) was downregulated in STZ rats. Treatment with CLP290 (a KCC2 activator) significantly lowered blood AVP and glucose levels in STZ rats. Last, investigation that used rats expressing an AVP-enhanced green fluorescent protein fusion gene showed that AVP synthesis in AVP neurons was much more intense in STZ rats than in control rats. We conclude that altered Cl- homeostasis that makes GABA excitatory and enhanced AVP synthesis are important changes in AVP neurons that would increase AVP secretion in DM. Our data suggest that Cl- transporters in AVP neurons are potential targets of antidiabetes treatments.


Asunto(s)
Arginina Vasopresina/metabolismo , Diabetes Mellitus Experimental/metabolismo , Neuronas GABAérgicas/metabolismo , Hipotálamo/metabolismo , Sistemas Neurosecretores/metabolismo , Núcleo Supraóptico/metabolismo , Animales , Arginina Vasopresina/sangre , Arginina Vasopresina/química , Arginina Vasopresina/genética , Diabetes Mellitus Experimental/tratamiento farmacológico , Diabetes Mellitus Experimental/patología , Diabetes Mellitus Experimental/fisiopatología , Fenómenos Electrofisiológicos/efectos de los fármacos , Neuronas GABAérgicas/efectos de los fármacos , Neuronas GABAérgicas/patología , Hipoglucemiantes/uso terapéutico , Hipotálamo/efectos de los fármacos , Hipotálamo/patología , Hipotálamo/fisiopatología , Proteínas Luminiscentes/química , Proteínas Luminiscentes/genética , Proteínas Luminiscentes/metabolismo , Masculino , Moduladores del Transporte de Membrana/uso terapéutico , Microscopía Fluorescente , Sistemas Neurosecretores/efectos de los fármacos , Sistemas Neurosecretores/patología , Sistemas Neurosecretores/fisiopatología , Oxitocina/química , Oxitocina/genética , Oxitocina/metabolismo , Profármacos/uso terapéutico , Ratas Sprague-Dawley , Ratas Transgénicas , Ratas Wistar , Proteínas Recombinantes de Fusión/química , Proteínas Recombinantes de Fusión/metabolismo , Estreptozocina , Núcleo Supraóptico/efectos de los fármacos , Núcleo Supraóptico/patología , Núcleo Supraóptico/fisiopatología , Simportadores/agonistas , Simportadores/metabolismo , Transmisión Sináptica/efectos de los fármacos , Cotransportadores de K Cl
5.
Brain Res Bull ; 134: 253-261, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28866293

RESUMEN

The perception and response to pain are severely impacted by exposure to stressors. In some animal models, stress increases pain sensitivity, which is termed stress-induced hyperalgesia (SIH). The insular cortex (IC) and anterior cingulate cortex (ACC), which are typically activated by noxious stimuli, affect pain perception through the descending pain modulatory system. In the present study, we examined the expression of phospho-cAMP response element-binding protein (pCREB) and early growth response 1 (Egr1) in the IC and ACC at 3h (the acute phase of peripheral tissue inflammation) after complete Freund's adjuvant (CFA) injection in naïve rats and rats preconditioned with forced swim stress (FS) to clarify the effect of FS, a stressor, on cortical cell activities in the rats showing SIH induced by FS. The CFA injection into the hindpaw induced mechanical hypersensitivity and increased the expression of the pCREB and Egr1 in the IC and ACC at 3h after the injection. FS (day 1, 10min; days 2-3, 20min) prior to the CFA injection enhanced the CFA-induced mechanical hypersensitivity and attenuated the increase in the expression of pCREB and Egr1 in the IC and ACC. These findings suggested that FS modulates the CFA injection-induced neuroplasticity in the IC and ACC to enhance the mechanical hypersensitivity. These findings are thought to signify stressor-induced dysfunction of the descending pain modulatory system.


Asunto(s)
Corteza Cerebral/metabolismo , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/metabolismo , Proteína 1 de la Respuesta de Crecimiento Precoz/metabolismo , Hiperalgesia/metabolismo , Estrés Psicológico/metabolismo , Animales , Corteza Cerebral/patología , Adyuvante de Freund , Neuronas GABAérgicas/metabolismo , Neuronas GABAérgicas/patología , Glutamato Descarboxilasa/metabolismo , Hiperalgesia/etiología , Hiperalgesia/patología , Inmunohistoquímica , Masculino , Plasticidad Neuronal , Fosforilación , Ratas Sprague-Dawley , Estrés Psicológico/complicaciones , Estrés Psicológico/patología , Natación/fisiología , Tacto
6.
Neurotox Res ; 30(3): 427-33, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27179799

RESUMEN

Methamphetamine (METH) is a psychostimulant drug with potent effects on the central nervous system that can cause psychotic symptoms similar to those of schizophrenia. Specific alterations in GABAergic neuronal markers have been reported in schizophrenia and animal models of psychotic illness. The aim of this study was to determine whether there are changes in subpopulations of GABAergic neurons, defined by the presence of calcium binding proteins (CBPs), in animal models of METH abuse. Rats received acute (Binge) doses of 4 × 6 mg/kg, a chronic escalating dose regime (0.1-4 mg/kg over 14 days) or a combination of the two and were compared with a vehicle-administered control group. Brains were taken and sections of frontal cortex (Cg1) and hippocampus (dentate gyrus and CA1-3 regions) underwent immunostaining for three CBPs [parvalbumin (PV), calbindin (CB), and calretinin (CR)]. Significant decreases in PV-immunoreactive (IR) neurons in each METH group and all regions were observed. Smaller METH-induced deficits in CB-IR cells were observed, reaching significance primarily following chronic METH regimes, while CR-IR was significantly reduced only in frontal cortex following chronic administration. These results suggest that METH regimes in rats can induce selective deficits in GABAergic neuronal subtypes similar to those seen in schizophrenia and may underlie the psychosis and/or cognitive impairment that can occur in METH abuse and dependence.


Asunto(s)
Trastornos Relacionados con Anfetaminas/metabolismo , Estimulantes del Sistema Nervioso Central/toxicidad , Lóbulo Frontal/efectos de los fármacos , Neuronas GABAérgicas/efectos de los fármacos , Hipocampo/efectos de los fármacos , Metanfetamina/toxicidad , Trastornos Relacionados con Anfetaminas/patología , Animales , Calbindina 2/metabolismo , Calbindinas/metabolismo , Modelos Animales de Enfermedad , Lóbulo Frontal/metabolismo , Lóbulo Frontal/patología , Neuronas GABAérgicas/metabolismo , Neuronas GABAérgicas/patología , Expresión Génica/efectos de los fármacos , Hipocampo/metabolismo , Hipocampo/patología , Inmunohistoquímica , Masculino , Parvalbúminas/metabolismo , Ratas Sprague-Dawley
7.
Neurobiol Dis ; 77: 141-54, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25766678

RESUMEN

Dravet Syndrome (DS) is caused by heterozygous loss-of-function mutations in voltage-gated sodium channel NaV1.1. Our mouse genetic model of DS recapitulates its severe seizures and premature death. Sleep disturbance is common in DS, but its mechanism is unknown. Electroencephalographic studies revealed abnormal sleep in DS mice, including reduced delta wave power, reduced sleep spindles, increased brief wakes, and numerous interictal spikes in Non-Rapid-Eye-Movement sleep. Theta power was reduced in Rapid-Eye-Movement sleep. Mice with NaV1.1 deleted specifically in forebrain interneurons exhibited similar sleep pathology to DS mice, but without changes in circadian rhythm. Sleep architecture depends on oscillatory activity in the thalamocortical network generated by excitatory neurons in the ventrobasal nucleus (VBN) of the thalamus and inhibitory GABAergic neurons in the reticular nucleus of the thalamus (RNT). Whole-cell NaV current was reduced in GABAergic RNT neurons but not in VBN neurons. Rebound firing of action potentials following hyperpolarization, the signature firing pattern of RNT neurons during sleep, was also reduced. These results demonstrate imbalance of excitatory vs. inhibitory neurons in this circuit. As predicted from this functional impairment, we found substantial deficit in homeostatic rebound of slow wave activity following sleep deprivation. Although sleep disorders in epilepsies have been attributed to anti-epileptic drugs, our results show that sleep disorder in DS mice arises from loss of NaV1.1 channels in forebrain GABAergic interneurons without drug treatment. Impairment of NaV currents and excitability of GABAergic RNT neurons are correlated with impaired sleep quality and homeostasis in these mice.


Asunto(s)
Modelos Animales de Enfermedad , Epilepsias Mioclónicas/complicaciones , Epilepsias Mioclónicas/patología , Interneuronas/patología , Trastornos del Sueño-Vigilia/etiología , Tálamo/patología , Factores de Edad , Animales , Animales Recién Nacidos , Estimulación Eléctrica , Epilepsias Mioclónicas/genética , Neuronas GABAérgicas/patología , Glutamato Descarboxilasa/metabolismo , Potenciales de la Membrana/genética , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Mutación/genética , Canal de Sodio Activado por Voltaje NAV1.1/genética , Técnicas de Placa-Clamp , Privación de Sueño/fisiopatología , Grabación en Video , Vigilia/genética
8.
Toxicology ; 328: 123-34, 2015 Feb 03.
Artículo en Inglés | MEDLINE | ID: mdl-25497112

RESUMEN

Hexachlorophene (HCP) is known to induce myelin vacuolation corresponding to intramyelinic edema of nerve fibers in the central and peripheral nervous system in animals. This study investigated the effect of maternal exposure to HCP on hippocampal neurogenesis in rat offspring using pregnant rats supplemented with 0 (controls), 100, or 300 ppm HCP in the diet from gestational day 6 to day 21 after delivery. On postnatal day (PND) 21, the numbers of T box brain 2(+) progenitor cells and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling(+) apoptotic cells in the hippocampal subgranular zone (SGZ) decreased in female offspring at 300 ppm, which was accompanied by myelin vacuolation and punctate tubulin beta-3 chain staining of nerve fibers in the hippocampal fimbria. In addition, transcript levels of the cholinergic receptor, nicotinic beta 2 (Chrnb2) and B-cell CLL/lymphoma 2 (Bcl2) decreased in the dentate gyrus. HCP-exposure did not alter the numbers of SGZ proliferating cells and reelin- or calcium-binding protein-expressing γ-aminobutyric acid (GABA)-ergic interneuron subpopulations in the dentate hilus on PND 21 and PND 77. Although some myelin vacuolation remained, all other changes observed in HCP-exposed offspring on PND 21 disappeared on PND 77. These results suggest that maternal HCP exposure reversibly decreases type-2b intermediate-stage progenitor cells via the mitochondrial apoptotic pathway in offspring hippocampal neurogenesis at 300 ppm HCP. Neurogenesis may be affected by dysfunction of cholinergic inputs into granule cell lineages and/or GABAergic interneurons as indicated by decreased transcript levels of Chrnb2 and numbers of Chrnb2(+) interneurons caused by myelin vacuolation in the septal-hippocampal pathway.


Asunto(s)
Fibras Colinérgicas/efectos de los fármacos , Hexaclorofeno/toxicidad , Hipocampo/efectos de los fármacos , Exposición Materna/efectos adversos , Vaina de Mielina/metabolismo , Células-Madre Neurales/efectos de los fármacos , Neurogénesis/efectos de los fármacos , Efectos Tardíos de la Exposición Prenatal , Vacuolas/efectos de los fármacos , Factores de Edad , Animales , Animales Recién Nacidos , Apoptosis/efectos de los fármacos , Linaje de la Célula , Fibras Colinérgicas/metabolismo , Fibras Colinérgicas/patología , Femenino , Neuronas GABAérgicas/efectos de los fármacos , Neuronas GABAérgicas/metabolismo , Neuronas GABAérgicas/patología , Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Edad Gestacional , Hipocampo/metabolismo , Hipocampo/patología , Interneuronas/efectos de los fármacos , Interneuronas/metabolismo , Interneuronas/patología , Células-Madre Neurales/metabolismo , Células-Madre Neurales/patología , Fenotipo , Embarazo , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , ARN Mensajero/metabolismo , Ratas , Receptores Nicotínicos/efectos de los fármacos , Receptores Nicotínicos/genética , Receptores Nicotínicos/metabolismo , Proteína Reelina , Tubulina (Proteína)/metabolismo , Vacuolas/metabolismo , Vacuolas/patología
9.
Ross Fiziol Zh Im I M Sechenova ; 101(10): 1135-49, 2015 Oct.
Artículo en Ruso | MEDLINE | ID: mdl-26827493

RESUMEN

The aim of the present study was to analyze a role of the ERK1/2 signaling pathway in the regulation of excitation and inhibitory neurons in the hippocampus and the temporal cortex of Krushinsky-Molodkina rats during seizure development finalizing with ataxia. Analysis was done by Western bloting as well as by immunohistochemistry. The results demonstrated significant up-regulation of ERK1/2 activity in the hippocampus in several seconds after sound stimulation. At the same time increased ERK1/2 activity was correlated with enhanced level of SNARE protein SNAP-25 and activation of synapsin I, the proteins which regulate exocytosis machinery. Decreased level of VGLUT2 associated with activation of ERK1/2 and exocytosis proteins supposed activation of glutamate release in the hippocampus, while in the temporal cortex diminished activity of ERK1/2 and synapsin I associated with VGLUT2 up-regulation assumed inhibition of glutamatergic transmission. Our data let us supposed that decreasing of glutamate release in th& temporal cortex could be a trigger for the inhibition of hippocampal glutamatergic system and the beginning of further ataxia stage. Our data demonstrated correlation between expression and activity of exocytosis proteins and ERK1/2 mainly in the glutamategic neurons of the hippocampus and the temporal cortex that let us proposed significant role of ERK1/2 kinases as a positive regulator of glutamate release and as a result initiation of seizure expression.


Asunto(s)
Ataxia/genética , Epilepsia Refleja/genética , Proteína Quinasa 1 Activada por Mitógenos/genética , Proteína Quinasa 3 Activada por Mitógenos/genética , Convulsiones/genética , Estimulación Acústica , Animales , Animales Endogámicos , Ataxia/metabolismo , Ataxia/patología , Epilepsia Refleja/metabolismo , Epilepsia Refleja/patología , Exocitosis/genética , Neuronas GABAérgicas/metabolismo , Neuronas GABAérgicas/patología , Regulación de la Expresión Génica , Ácido Glutámico/metabolismo , Hipocampo/metabolismo , Hipocampo/patología , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Ratas , Convulsiones/metabolismo , Convulsiones/patología , Transducción de Señal , Sinapsinas/genética , Sinapsinas/metabolismo , Proteína 25 Asociada a Sinaptosomas/genética , Proteína 25 Asociada a Sinaptosomas/metabolismo , Lóbulo Temporal/metabolismo , Lóbulo Temporal/patología , Proteína 2 de Transporte Vesicular de Glutamato/genética , Proteína 2 de Transporte Vesicular de Glutamato/metabolismo , Ácido gamma-Aminobutírico/metabolismo
10.
Biomedica ; 34(2): 207-17, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24967926

RESUMEN

INTRODUCTION: Cerebral ischemia is the third leading cause of death and the primary cause of permanent disability worldwide. Atorvastatin is a promising drug with neuroprotective effects that may be useful for the treatment of stroke. However, the effects of atorvastatin on specific neuronal populations within the nigrostriatal system following cerebral ischemia are unknown. OBJECTIVE: To evaluate the effects of atorvastatin on dopaminergic and GABAergic neuronal populations in exofocal brain regions in a model of transient occlusion of the middle cerebral artery. MATERIALS AND METHODS: Twenty-eight male eight-week-old Wistar rats were used in this study. Both sham and ischemic rats were treated with atorvastatin (10 mg/kg) or carboxymethylcellulose (placebo) by gavage at 6, 24, 48 and 72 hours post-reperfusion. We analyzed the immunoreactivity of glutamic acid decarboxylase and tyrosine hydroxylase in the globus pallidus, caudate putamen and substantia nigra. RESULTS: We observed neurological damage and cell loss in the caudate putamen following ischemia. We also found an increase in tyrosine hydroxylase immunoreactivity in the medial globus pallidus and substantia nigra reticulata, as well as a decrease in glutamic acid decarboxylase immunoreactivity in the lateral globus pallidus in ischemic animals treated with a placebo. However, atorvastatin treatment was able to reverse these effects, significantly decreasing tyrosine hydroxylase levels in the medial globus pallidus and substantia nigra reticulata and significantly increasing glutamic acid decarboxylase levels in the lateral globus pallidus. CONCLUSION: Our data suggest that post-ischemia treatment with atorvastatin can have neuro-protective effects in exofocal regions far from the ischemic core by modulating the GABAergic and dopaminergic neuronal populations in the nigrostriatal system, which could be useful for preventing neurological disorders.


Asunto(s)
Cuerpo Estriado/efectos de los fármacos , Neuronas Dopaminérgicas/efectos de los fármacos , Neuronas GABAérgicas/efectos de los fármacos , Ácidos Heptanoicos/uso terapéutico , Infarto de la Arteria Cerebral Media/tratamiento farmacológico , Ataque Isquémico Transitorio/tratamiento farmacológico , Fármacos Neuroprotectores/uso terapéutico , Pirroles/uso terapéutico , Sustancia Negra/efectos de los fármacos , Animales , Atorvastatina , Conducta Animal , Cuerpo Estriado/irrigación sanguínea , Cuerpo Estriado/patología , Neuronas Dopaminérgicas/enzimología , Neuronas Dopaminérgicas/patología , Evaluación Preclínica de Medicamentos , Inducción Enzimática/efectos de los fármacos , Neuronas GABAérgicas/enzimología , Neuronas GABAérgicas/patología , Glutamato Descarboxilasa/biosíntesis , Glutamato Descarboxilasa/genética , Ácidos Heptanoicos/farmacología , Infarto de la Arteria Cerebral Media/patología , Ataque Isquémico Transitorio/patología , Masculino , Trastornos del Movimiento/etiología , Trastornos del Movimiento/prevención & control , Proteínas del Tejido Nervioso/biosíntesis , Proteínas del Tejido Nervioso/genética , Fármacos Neuroprotectores/farmacología , Pirroles/farmacología , Ratas , Ratas Wistar , Recuperación de la Función , Trastornos de la Sensación/etiología , Trastornos de la Sensación/prevención & control , Organismos Libres de Patógenos Específicos , Sustancia Negra/irrigación sanguínea , Sustancia Negra/patología , Tirosina 3-Monooxigenasa/biosíntesis , Tirosina 3-Monooxigenasa/genética
11.
Biomédica (Bogotá) ; 34(2): 207-217, abr.-jun. 2014. ilus, graf
Artículo en Inglés | LILACS | ID: lil-712403

RESUMEN

Introduction: Cerebral ischemia is the third leading cause of death and the primary cause of permanent disability worldwide. Atorvastatin is a promising drug with neuroprotective effects that may be useful for the treatment of stroke. However, the effects of atorvastatin on specific neuronal populations within the nigrostriatal system following cerebral ischemia are unknown. Objective: To evaluate the effects of atorvastatin on dopaminergic and GABAergic neuronal populations in exofocal brain regions in a model of transient occlusion of the middle cerebral artery. Materials and methods: Twenty-eight male eight-week-old Wistar rats were used in this study. Both sham and ischemic rats were treated with atorvastatin (10 mg/kg) or carboxymethylcellulose (placebo) by gavage at 6, 24, 48 and 72 hours post-reperfusion. We analyzed the immunoreactivity of glutamic acid decarboxylase and tyrosine hydroxylase in the globus pallidus, caudate putamen and substantia nigra. Results: We observed neurological damage and cell loss in the caudate putamen following ischemia. We also found an increase in tyrosine hydroxylase immunoreactivity in the medial globus pallidus and substantia nigra reticulata, as well as a decrease in glutamic acid decarboxylase immunoreactivity in the lateral globus pallidus in ischemic animals treated with a placebo. However, atorvastatin treatment was able to reverse these effects, significantly decreasing tyrosine hydroxylase levels in the medial globus pallidus and substantia nigra reticulata and significantly increasing glutamic acid decarboxylase levels in the lateral globus pallidus. Conclusion: Our data suggest that post-ischemia treatment with atorvastatin can have neuro-protective effects in exofocal regions far from the ischemic core by modulating the GABAergic and dopaminergic neuronal populations in the nigrostriatal system, which could be useful for preventing neurological disorders.


Introducción. La isquemia cerebral es la tercera causa de muerte y la primera de discapacidad permanente en el mundo. La atorvastatina es un fármaco neuroprotector prometedor para el tratamiento de la apoplejía; sin embargo, su acción sobre las poblaciones neuronales del sistema nigroestriatal después de la isquemia aún se desconoce. Objetivo. Evaluar el efecto de la atorvastatina sobre poblaciones gabérgicas y dopaminérgicas en regiones exofocales en un modelo de oclusión transitoria de la arteria cerebral media. Materiales y métodos. Se utilizaron 28 ratas Wistar macho de ocho semanas de edad. Los ejemplares con isquemia simulada y los ejemplares sometidos a isquemia fueron tratados con atorvastatina (10 mg/kg) y carboximetilcelulosa (placebo) administrados por medio de sonda a las 6, 24, 48 y 72 horas después de la reperfusión. Se analizó la inmunorreacción de la descarboxilasa del ácido glutámico y de la tirosina hidroxilasa en el globo pálido, el putamen caudado y la sustancia negra. Resultados. Los datos confirmaron el daño neurológico y la pérdida celular en el putamen caudado. Se incrementó la inmunorreacción de la tirosina hidroxilasa en el globo pálido medial y la sustancia negra pars reticulata , disminuyendo la inmunorreacción de la descarboxilasa del ácido glutámico en el globo pálido lateral de los animales isquémicos tratados con placebo; sin embargo, el tratamiento con atorvastatina pudo revertirla, lo que logró una disminución significativa de la tirosina hidroxilasa en el globo pálido medial y la sustancia negra pars reticulata y aumentando los niveles de descarboxilasa del ácido glutámico en el globo pálido lateral. Conclusión. Nuestros datos sugieren que la atorvastatina en el tratamiento posterior a la isquemia ejerce neuroprotección en las zonas exofocales, modulando las poblaciones neuronales gabérgicas y dopaminérgicas del sistema nigroestriatal, lo que podría prevenir trastornos neurológicos.


Asunto(s)
Animales , Masculino , Ratas , Cuerpo Estriado/efectos de los fármacos , Neuronas Dopaminérgicas/efectos de los fármacos , Neuronas GABAérgicas/efectos de los fármacos , Ácidos Heptanoicos/uso terapéutico , Infarto de la Arteria Cerebral Media/tratamiento farmacológico , Ataque Isquémico Transitorio/tratamiento farmacológico , Fármacos Neuroprotectores/uso terapéutico , Pirroles/uso terapéutico , Sustancia Negra/efectos de los fármacos , Conducta Animal , Cuerpo Estriado/irrigación sanguínea , Cuerpo Estriado/patología , Evaluación Preclínica de Medicamentos , Neuronas Dopaminérgicas/enzimología , Neuronas Dopaminérgicas/patología , Inducción Enzimática/efectos de los fármacos , Neuronas GABAérgicas/enzimología , Neuronas GABAérgicas/patología , Glutamato Descarboxilasa/biosíntesis , Glutamato Descarboxilasa/genética , Ácidos Heptanoicos/farmacología , Infarto de la Arteria Cerebral Media/patología , Ataque Isquémico Transitorio/patología , Trastornos del Movimiento/etiología , Trastornos del Movimiento/prevención & control , Proteínas del Tejido Nervioso/biosíntesis , Proteínas del Tejido Nervioso/genética , Fármacos Neuroprotectores/farmacología , Pirroles/farmacología , Ratas Wistar , Recuperación de la Función , Organismos Libres de Patógenos Específicos , Trastornos de la Sensación/etiología , Trastornos de la Sensación/prevención & control , Sustancia Negra/irrigación sanguínea , Sustancia Negra/patología , /biosíntesis , /genética
12.
Mol Brain ; 6: 43, 2013 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-24228616

RESUMEN

BACKGROUND: The selective serotonin reuptake inhibitor fluoxetine (FLX) is widely used to treat depression and anxiety disorders, but cellular mechanisms underlying the antidepressant effect of FLX remain largely unknown. The generally accepted effect of chronic FLX treatment is increased adult neurogenesis in the hippocampal dentate gyrus. It was recently demonstrated that FLX treatments can reverse the established neuronal maturation of granule cells in the hippocampal dentate gyrus and of gamma-aminobutyric acidergic (GABAergic) interneurons in the basolateral amygdala. However, it is not clear whether this dematuration effect of FLX occurs in other brain regions. Thus, in this study, we used immunohistological analysis to assess the effect of FLX treatment on GABAergic interneurons in the medial frontal cortex (mFC) and reticular thalamic nucleus (RTN). RESULTS: Immunofluorescence analysis for perineuronal nets (PNNs), which is a marker of neuronal maturation, and for parvalbumin, calretinin, and somatostatin, which are markers for specific GABAergic interneuron type, showed lower number of parvalbumin-positive (+) cells and PNN+/parvalbumin+ cells in the mFC of FLX-treated mice compared to vehicle-treated mice. However, FLX treatment had no effect on the number of cells expressing calretinin and somatostatin in the mFC. In the RTN, the number of PNN+ cells and parvalbumin+ cells was unaltered by FLX treatments. Furthermore, the number of total GABA+ cells and apoptotic cells in the mFC was similar between vehicle- and FLX-treated mice, suggesting that FLX treatment did not induce cell death in this region. Rather, our findings suggest that the decreased number of parvalbumin+ cells in the mFC was due to a decreased expression of parvalbumin proteins in the interneurons. CONCLUSIONS: This study indicates that FLX decreases the levels of parvalbumin, a mature marker of fast-spiking interneurons, and PNNs in parvalbumin+ interneurons in the mFC, suggesting that FLX treatment induces a dematuration of this type of neurons. Induction of a juvenile-like state in fast-spiking inhibitory interneurons in these regions might be involved in the therapeutic mechanism of this antidepressant drug and/or some of its adverse effects.


Asunto(s)
Envejecimiento/metabolismo , Fluoxetina/farmacología , Lóbulo Frontal/metabolismo , Neuronas GABAérgicas/metabolismo , Interneuronas/metabolismo , Parvalbúminas/metabolismo , Animales , Apoptosis/efectos de los fármacos , Región CA3 Hipocampal/efectos de los fármacos , Región CA3 Hipocampal/metabolismo , Región CA3 Hipocampal/patología , Calbindina 2/metabolismo , Recuento de Células , Fluoxetina/administración & dosificación , Lóbulo Frontal/efectos de los fármacos , Neuronas GABAérgicas/patología , Interneuronas/efectos de los fármacos , Interneuronas/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Modelos Biológicos , Somatostatina/metabolismo , Tálamo/efectos de los fármacos , Tálamo/metabolismo , Tálamo/patología , Ácido gamma-Aminobutírico/metabolismo
13.
CNS Spectr ; 18(1): 15-20, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23593652

RESUMEN

Dyskinesia is an extrapyramidal movement disorder characterized by involuntary, repetitive, irregular motions that affect the mouth and face and/ or the limbs and trunk. Tardive dyskinesia (TD) is a well-known complication of long term treatment with antipsychotic drugs. Dyskinesia is also induced with levodopa, a treatment for Parkinson's disease,and it occurs spontaneously as a symptom of Huntington's disease. Research on the pathogenesis of TD has focused on a dysfunction of either the dopaminergic or serotonergic system. However, recent evidence has suggested that we should focus on the possible damage of GABAergic medium spiny neurons (MSNs). MSNs are the first station in the corticostriato-thalamo-cortical circuit that regulates the amplitude and velocity of movements. Two pathways can be distinguished in this circuit: a direct pathway, which increases movements (hyperkinesia), and an indirect pathway,which decreases movements (hypokinesia). Both pathways are activated by glutamatergic corticostriatal neurons. Here,we discuss some evidence that supports the hypothesis that indirect pathway MSNs are damaged in dyskinesia.


Asunto(s)
Discinesia Inducida por Medicamentos/patología , Neuronas GABAérgicas/patología , Vías Nerviosas/fisiología , Antiparkinsonianos/efectos adversos , Corteza Cerebral/patología , Cuerpo Estriado/patología , Neuronas GABAérgicas/efectos de los fármacos , Neuronas GABAérgicas/fisiología , Ácido Glutámico/metabolismo , Humanos , Levodopa/efectos adversos , Vías Nerviosas/efectos de los fármacos , Tálamo/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA